Venus Remedies

Venus Remedies EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Venus Remedies (VENUSREM.NS) as of Nov 9, 2026 is 1.22 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 635.36 M INR — a change of 91.47% (higher).

EBITDA

1.22 BINR

YoY

91.47%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Venus Remedies is 2026 1.22 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Venus Remedies was 2025 635.36 M INR. It decreases by 91.47% higher compared to the previous year.

The Venus Remedies EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
267.56 M INR
Jan 1, 2020
431.89 M INR
Jan 1, 2021
591.78 M INR
Jan 1, 2022
701.36 M INR
Jan 1, 2023
703.46 M INR
Jan 1, 2024
711.80 M INR
Jan 1, 2025
635.36 M INR
Jan 1, 2026
1.22 B INR
The Venus Remedies EBITDA history
YEAREBITDAYoY
1.22 BINR+91.47%
635.36 MINR-10.74%
711.80 MINR+1.19%
703.46 MINR+0.30%
701.36 MINR+18.52%
591.78 MINR+37.02%
431.89 MINR+61.41%
267.56 MINR-33.32%
401.24 MINR-9.76%
444.65 MINR-1.60%
451.87 MINR-7.11%
486.48 MINR-55.49%
1.09 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Venus Remedies is 1.22 B INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Venus Remedies changed from 635.36 M INR to 1.22 B INR, representing a 91.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Venus Remedies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Venus Remedies

All Key Metrics — Venus Remedies